Global Leukemia Therapeutics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Disease Condition, Diagnosis, Treatments, Drugs & Region - Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 764
Pages: 175

Global Leukemia Therapeutics Market Size (2024 to 2029)

The global leukemia therapeutics market is expected to be worth USD 13.86 billion by 2029 and USD 8.8 billion in 2024, growing at a CAGR of 9.5% from 2024 to 2029.

Current Scenario of the Global Leukemia Therapeutics Market

Leukemia is a blood-forming tissue cancer that affects the blood components and bone marrow. When the bone marrow generates damaged lymphocytes, antibodies are defective, and the body's capacity to fight infections is lost. Leukemia is rising as a life-threatening concern around the globe, among other cancer forms. The leukemia therapeutics includes a variety of therapies recommended by doctors for the treatment of leukemia. Various circumstances, including genetic mutations and a family history of the disease, cause leukemia. Leukemia occurs most often in adults older than 55, but it is the most common cancer in children younger than 15 years. 


The growing global aging population, which results in leukemia prevalence, is majorly driving the growth of the leukemia therapeutics market.

The disease occurrence is primarily seen in middle-aged people and senior citizens. The rising prevalence of different leukemia cancers, such as acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia, and chronic myeloid leukemia, contributes majorly to the global market expansion. The growing research in the leukemia industry is raising the launch of new products, enhancing the growth of global size. According to U.S. Cancer Statistics Data, in September 2022, stated that acute lymphocytic leukemia is more prevalent in children less than 15 years of age, Hodgkin and Non-Hodgkin lymphomas are prevalent in people aged 15 to 39 years, and people above 40 years people are more prone to Non-Hodgkin lymphoma. The prevalence of the disease in older adults and children is accelerating the adoption of leukemia therapeutics, expanding the global market size expansion.

The introduction of innovative therapies that are effective nowadays, such as bone marrow transplant and stem cell therapy, are the upcoming trends in the leukemia therapeutics market, which are expected to augment the market. Various researchers state that leukemia is the 11th most frequent cause of cancer-related mortality and the 15th most frequent cause of cancer incidence worldwide. The rising prevalence of chronic lymphocytic leukemia in various regions raises the demand for leukemia therapeutics, positively impacting market expansion. The improving healthcare infrastructure of developing nations, the growing awareness among the people regarding cancers and their treatment procedures, and escalating government initiatives to support cancer people are accelerating the market share growth. The growing investments by the market players in R&D activities to develop different efficient treatment therapies are gaining traction. The researchers focus on developing the existing drugs by enhancing their efficiency and safety, majorly driving the global market growth.

The enhancing demand for combination therapies such as immunotherapy and chemotherapy, which are expected to significantly affect the treatment of leukemia, is creating a market opportunity for leukemia market growth. The rising technological advancements and introduction and development of innovative and effective targeted therapies and immunotherapies are accelerating the market expansion by providing lucrative growth to leukemia treatment. 


The need for awareness and the necessity of early diagnosis where people from developing regions are left untreated and late diagnosis is hampering the global market growth. Additionally, high treatment costs and drug costs hinder the growth of the global leukemia therapeutics market. The limited treatment options and the availability of generic forms of drugs restrain the growth of the global leukemia therapeutics market. The development of generic forms will restrict the adoption of price variations for branded drugs, negatively impacting market size growth. The side effects associated with the therapeutic drugs are estimated to limit the expansion of the global leukemia therapeutics market due to the limited adoption rate. The availability of various other treatment methods is restricting the possibility of market expansion. 

Stringent regulations for the approval and development of new drug moieties, leading to product delays, more time consumption, and pricing variations, are all significant challenges for manufacturers in expanding the leukemia market. The new treatment methods for leukemia face various challenges from the regulatory authorities, which can be expensive and negatively impact market growth. 

Impact of COVID-19 on the Global Leukemia Therapeutics Market

The COVID-19 pandemic has positively and negatively impacted the healthcare sector. Various governments worldwide have imposed strict lockdowns to control the spread of the coronavirus, resulting in an imbalance in the demand and supply of pharmaceutical products in the healthcare industry. Most companies have manufacturing facilities in developed countries such as the United States, the United Kingdom, and Germany, where the pandemic has significantly affected company profits for various healthcare products. Furthermore, as the number of non-COVID-19 patients in hospitals declined, the number of procedures and prescriptions for disease treatments decreased. Besides that, according to the U.K. Coronavirus Cancer Monitoring Project (UKCCMP), blood cancer patients, particularly those with leukemia, multiple myeloma, and lymphoma, are at a greater risk of acquiring the COVID-19 virus, increasing the demand for leukemia therapeutics. As a result of these and other similar results, demand for leukemia therapeutics has increased during the COVID-19 pandemic, with market players reporting increased sales.




Market Size Available

2023 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Covered

By Disease Condition, Diagnosis, Treatments, Drugs and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Key Market Players

F. Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.



Global Leukemia Therapeutics Market Analysis – By Disease Condition

The chronic myeloid leukemia segment dominated the global leukemia therapeutics market owing to its high prevalence rate. High prevalence rates, the availability of high-dose drug therapies, and the fast uptake of second-generation tyrosine kinase inhibitors are significant factors driving the segment's tremendous growth. The growing aging population, increasing investments in cancer research, and growing adoption of bone marrow transplantation for treatment are driving segment growth, leading to global market share growth. 

Acute lymphatic leukemia is estimated to have the fastest growth during the forecast period due to increasing prevalence in younger people below 15 years of age. The disease progresses rapidly, and if not treated in time, the disease can be fatal, which gives the term "acute" to the disease. The growing introduction of novel therapeutics and escalating awareness among people regarding cancer and its therapeutic procedures are expected to boost the market value.   

Global Leukemia Therapeutics Market Analysis – By Diagnosis

The MRI segment had the largest share of the global leukemia therapeutics market in 2023, and this trend is expected to continue throughout the forecast period. MRI is better than X-rays or CT scans when doctors need a view of soft tissues. Compared to CT images, MRIs can provide more precise images of organs and soft tissues, such as torn ligaments and herniated discs.

The CT scan segment is expected to grow steadily during the forecast period due to its broad adoption among healthcare professionals and lower cost than the MRI, which is prominently escalating the segment's growth. 

Global Leukemia Therapeutics Market Analysis – By Treatment 

The chemotherapy segment dominated the global leukemia therapeutics market revenue in 2023, as chemotherapy is the primary form of treatment for most leukemia patients. Chemotherapy is a promising segment due to its ability to kill cancerous cells or inhibit their proliferation while maintaining an average lymphocyte level in chemotherapy. 

The stem cell therapy and bone marrow transplant segments are projected to grow fastest, with a significant CAGR during the forecast period. Based on treatments, these segments are emerging trends in the leukemia therapeutics market. The accelerating innovations in cancer research are enhancing the effective treatment procedures for leukemia, propelling the global market size growth.

The targeted and immunotherapy segments are estimated to have steady growth during the forecast period and a prominent market share. The rising adoption of targeted immunotherapies for cancer treatment due to minimal side effects will enhance the market growth opportunities over the forecast in these segments. 

Global Leukemia Therapeutics Market Analysis – By Drugs

The Gleevec segment was one of the significant contributors to global market growth and is predicted to continue leading during the forecast period.


North America holds the largest share of the global leukemia therapeutics market, followed by Europe. Factors such as the rising prevalence of cancer, growing awareness of leukemia cancer screening programs, and government support drive the growth of the Leukemia therapeutics market in the North American region. The presence of key market players in the United States, advanced healthcare infrastructure in the U.S. and Canada, and the growing research investments by the market players in developing innovative and effective therapies for leukemia are estimated to propel the regional market growth. According to the Leukemia & Lymphoma Society, an estimated 381,774 people are living with or in remission from leukemia in the U.S. The Canadian government is making considerable investments in leukemia research to develop novel immunotherapies in leukemia treatment.   

The European market is predicted to be the second-most promising regional market globally. The rapid growth of the European countries can be attributed to consumers' increasing awareness of effective therapeutics' availability in the coming years. The availability of advanced and prominent healthcare facilities across the region and growing government initiatives by investing in R&D for cancer are estimated to augment the European market. Germany is considered aa hub for pharmaceuticals where the key market players are present, and significant R&D institutes for cancer are accelerating the market growth opportunities across the region. 

Asia Pacific market is proliferating due to the rising consumer market, increasing the aging population, and raising awareness for healthcare among the region's developing nations. Furthermore, developing healthcare infrastructure in emerging economies offers promising growth opportunities for Asia Pacific market players. The rising contribution from China, India, and Japan and growing investments in research and development are expected to boost the Asia Pacific leukemia therapeutics market in the coming years. Additionally, rising consumer disposable income and the growing prevalence of leukemia are expected to drive market growth over the forecast period.


Some of the prominent companies dominating the global leukemia therapeutics market profiled in this report are F. Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.


  • In January 2023, The New South Wales (NSW) Government invested USD 3.75 million in a clinical trial focused on helping older adults with acute myeloid leukemia. This trial aimed to develop new drug combinations to improve the longevity of patients who are intolerant to aggressive chemotherapy. 
  • In May 2023, Bristol-Myers Squibb Co. announced its primary Phase ½ of the Breyanzi study results. The drug is developed to treat patients with chronic lymphocytic leukemia. 
  • In August 2023, researchers at the University of Pennsylvania's Perelman School of Medicine conducted preclinical tests to expand the use of CAR-T cell therapy. This test is primarily aimed at treating a broad spectrum of blood cancers, advancing leukemia treatment options in the market. 
  • In September 2022, Oryzon Genomics conducted a study trial to assess the safety and efficacy of RP2D with iadademstat and gilteritinib in FLT3-mutated recurrent acute myeloid leukemia. 
  • In September 2018, Blinatumomab received approval in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. 
  • The EU approved BLINCYTO (Blinatumomab) in January 2019 for patients with Philadelphia chromosome-negative minimal residual disease, a definite B-cell precursor acute lymphoblastic leukemia. BLINCYTO is the only therapy the EU has approved for minimal residual disease treatment. 
  • Celgene Corporation signed a deal in July 2017 to develop and commercialize Beigenes' investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317, for patients with solid tumors.


This research report on the global leukemia therapeutics market has been segmented and sub-segmented based on the disease condition, diagnosis, treatments, drugs, and region.

By Disease Condition

  • Chronic Lymphatic Leukemia
  • Acute Lymphatic Leukemia
  • Chronic Myeloid Leukemia 
  • Acute Myeloid Leukemia

By Diagnosis

  • CT scan
  • Biopsy
  • MRI

By Treatments

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Surgery
  • Targeted Therapy
  • Bone marrow transplant
  • Stem Cell Therapy

By Drugs

  • Gleevec
  • Sapacitabine
  • GA101
  • Vasaroxine
  • Tosedosat

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample